enalapril and Aortic-Valve-Insufficiency

Aortic regurgitation resulting from blunt chest trauma has been reported only 95 times, to our knowledge. The noncoronary and right coronary cusps are the cardiac structures most often injured. Although the aortic leaflets can appear to be undamaged after nonpenetrating trauma, they can have pathologic abnormalities and insufficient function. Some cases of posttraumatic aortic regurgitation progress slowly. Aortic valve replacement is the optimal treatment. We present the case of a then-62-year-old man who has lived more than 5 years after blunt-trauma aortic regurgitation. His is the only case of long-term survival on medical therapy alone among the 96 cases summarized in this report.

Topics: Accidents, Traffic; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aortic Valve; Aortic Valve Insufficiency; Drug Therapy, Combination; Echocardiography, Doppler, Color; Echocardiography, Transesophageal; Enalapril; Female; Heart Injuries; Humans; Imidazoles; Male; Middle Aged; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Wounds, Nonpenetrating; Young Adult

This review has been focused on the new insights in the pathophysiology of mitral and aortic regurgitation and on the role of ACE-inhibitor therapy in children with chronic volume overload due to left-sided valvular lesions. Recent clinical studies show that these drugs have favorable effects when administered orally in chronic mitral and aortic regurgitation. Interestingly, the beneficial effects of ACE-inhibition regard the basic anatomic, hemodynamic and adaptive pathologic conditions related to volume overload, namely, the regurgitant orifice area and volume and ventricular remodeling. The heart is a plastic structure, constantly being altered in size, shape and composition in response to chronic volume overload. Thus, modulation of cardiac plasticity by ACE-inhibition raises the possibility of using new therapeutic strategies specifically designed to prevent and/or antagonize the mechanical disadvantages secondary to volume overload-induced cardiac remodeling. The beneficial effects of ACE-inhibition have also been observed in growing children with asymptomatic valvular regurgitation; thus, it appears that the unloading therapy has the potential of influencing the natural history of both mitral and aortic regurgitation and possibly delays surgical valve repair or replacement. These data justify early inhibition of the renin-angiotensin system in children with left ventricular volume overload due to mitral and aortic regurgitation.

Topics: Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Insufficiency; Child; Chronic Disease; Enalapril; Hemodynamics; Humans; Mitral Valve Insufficiency; Renin-Angiotensin System; Ventricular Dysfunction, Left

Vasodilator therapy can reduce the left ventricular volume and mass and improve left ventricular performance in patients with aortic regurgitation. Accordingly, it has been suggested that such therapy may reduce or delay the need for aortic-valve replacement.. We randomly assigned 95 patients with asymptomatic severe aortic regurgitation and normal left ventricular function to receive open-label nifedipine (20 mg every 12 hours), open-label enalapril (20 mg per day), or no treatment (control group) to identify the possible beneficial effects of vasodilator therapy on left ventricular function and the need for aortic-valve replacement.. After a mean of seven years of follow-up, the rate of aortic-valve replacement was similar among the groups: 39 percent in the control group, 50 percent in the enalapril group, and 41 percent in the nifedipine group (P=0.62). In addition, there were no significant differences among the groups in aortic regurgitant volume, left ventricular size, left ventricular mass, mean wall stress, or ejection fraction. One year after valve replacement, the left ventricular end-diastolic diameter and end-systolic diameter had decreased to a similar degree among the patients who underwent surgery in each of the three groups, and all the patients had a normal ejection fraction.. Long-term vasodilator therapy with nifedipine or enalapril did not reduce or delay the need for aortic-valve replacement in patients with asymptomatic severe aortic regurgitation and normal left ventricular systolic function. Furthermore, such therapy did not reduce the aortic regurgitant volume, decrease the size of the left ventricle, or improve left ventricular function.

Topics: Actuarial Analysis; Adult; Aortic Valve Insufficiency; Blood Pressure; Enalapril; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Hemodynamics; Humans; Male; Middle Aged; Nifedipine; Treatment Failure; Vasodilator Agents; Ventricular Function, Left

This study examined whether long-term therapy with an angiotensin-converting enzyme (ACE) inhibitor reduces excessive increases in left ventricular (LV) mass as well as volume in growing children with aortic regurgitation or mitral regurgitation.. The ACE inhibitor reduces volume overload and LV hypertrophy in adults with aortic or mitral regurgitation.. This study included 24 patients whose ages ranged from 0.3 to 16 years at entry to the study. On echocardiography, we measured LV size, systolic function and mass. After obtaining baseline data, patients were allocated into two groups. Twelve patients were given an ACE inhibitor (ACE inhibitor group), and 12 patients were not (control group). Echo parameters were again assessed after an average 3.4 years of follow-up.. Left ventricular parameters at baseline in the two groups were similar. The Z value of LV end-diastolic dimensions decreased from +0.82 +/- 0.55 to +0.57 +/- 0.58 in the ACE inhibitor group, whereas it increased from +0.73 +/- 0.85 to +1.14 +/- 1.04 in the control group (mean change -0.25 +/- 0.33 for the ACE inhibitor group vs. +0.42 +/- 0.48 for the control group, p = 0.0007). The mass normalized to growth also reduced from 221 +/- 93% to 149 +/- 44% of normal in the ACE inhibitor group and increased from 167 +/- 46% to 204 +/-59% of normal in the control group (mean change -72 +/- 89% of normal for the ACE inhibitor group vs. +37 +/- 35% of normal for the control group, p = 0.0007).. Long-term treatment with ACE inhibitors is effective in reducing not only LV volume overload but also LV hypertrophy in the hearts of growing children with LV volume overload.

Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Insufficiency; Child; Child, Preschool; Cilazapril; Disease Progression; Echocardiography; Enalapril; Follow-Up Studies; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Infant; Mitral Valve Insufficiency; Myocardial Contraction; Observer Variation; Pilot Projects; Treatment Outcome; Ventricular Function, Left

This study attempted to evaluate the long-term efficacy of enalapril versus hydralazine therapy on left ventricular volume, mass and function as well as on the renin-angiotensin system in chronic asymptomatic aortic regurgitation.. We tested the hypothesis that early administration of a vasodilator drug might be able to reduce left ventricular dilation and mass expansion. Because the renin-angiotensin system may be activated in chronic aortic regurgitation, early enalapril therapy might be beneficial.. Between 1990 and 1993, 76 asymptomatic nonrheumatic patients with mild to severe chronic aortic regurgitation were enrolled in a randomized, double-blind trial comparing enalapril with hydralazine. All patients underwent serial noninvasive studies. Seventy patients completed the 12-month follow-up.. At 1 year, patients receiving enalapril had a significant reduction in left ventricular end-diastolic and end-systolic volume indexes (124 +/- 15 vs. 108 +/- 17 ml/m2, p < 0.01; 50 +/- 12 vs. 40 +/- 14 ml/m2, p < 0.01, respectively) and mass index (131 +/- 16 vs. 113 +/- 19 g/m2, p < 0.01), whereas hydralazine therapy showed no significant changes. Both regimens not only had a significant reduction in left ventricular mean wall stress but also had a mild increase in exercise duration. Only enalapril therapy achieved a significant inhibition of the renin-angiotensin system, in contrast to hydralazine therapy. Moreover, the multiple r2 value from the analysis for end-diastolic volume index using the two variables of age and treatment drugs was 72.1% (p < 0.01).. Both regimens decrease left ventricular mean wall stress. Enalapril therapy achieves significant left ventricular mass regression, left ventricular end-diastolic and end-systolic volume index reduction and renin-angiotensin system suppression. These findings suggest that early unloading enalapril therapy has the potential to favorably influence the natural history of chronic aortic regurgitation.

Topics: Aged; Aortic Valve Insufficiency; Chronic Disease; Double-Blind Method; Echocardiography; Enalapril; Female; Follow-Up Studies; Hemodynamics; Humans; Hydralazine; Male; Middle Aged; Renin-Angiotensin System; Vasodilator Agents; Ventricular Function, Left

Topics: Aortic Valve Insufficiency; Blood Pressure; Enalapril; Heart Valve Prosthesis Implantation; Humans; Nifedipine; Vasodilator Agents; Ventricular Function, Left

Topics: Aortic Valve Insufficiency; Blood Pressure; Enalapril; Heart Valve Prosthesis Implantation; Heart Ventricles; Humans; Nifedipine; Patient Dropouts; Vasodilator Agents

Topics: Antihypertensive Agents; Aortic Valve Insufficiency; Disease Progression; Enalapril; Humans; Hypertension; Nifedipine; Vasodilator Agents

Topics: Aortic Valve Insufficiency; Enalapril; Humans; Hypertrophy, Left Ventricular; Nifedipine; Vasodilator Agents

Topics: Aortic Valve Insufficiency; Enalapril; Heart Valve Prosthesis Implantation; Humans; Nifedipine; Treatment Failure; Vasodilator Agents

Long-term treatment with angiotensin-converting enzyme (ACE) inhibitors has beneficial effects in patients with chronic aortic regurgitation by reducing left ventricular volumes and regurgitant fraction. Velocity-encoded cine magnetic resonance imaging can directly measure antegrade (forward stroke volume) and retrograde blood flow (regurgitant volume) in the ascending aorta. Velocity-encoded cine magnetic resonance imaging was used in 9 patients with moderate to severe aortic regurgitation (regurgitant fraction 49% +/- 17%) to measure regurgitant fraction, regurgitant volume, and forward stroke volume at baseline and 3 months after therapy with enalapril (mean dose 29 +/- 13 mg). Ten additional patients with aortic regurgitation without any drug therapy served as a control group. In the treatment group, systolic blood pressure slightly decreased from 132 +/- 20 mm Hg to 121 +/- 14 mm Hg (p = not significant), whereas diastolic blood pressure and heart rate (beats per minute) remained unchanged. Regurgitant fraction decreased in 6 patients (responders) from 49% +/- 19% to 39% +/- 20% (percentage change 24% +/- 14%, p = 0.002) and was unchanged in 3 patients (nonresponder, 49% +/- 19% vs 51% +/- 16%; p = not significant). In the responder group, forward stroke volume increased from 128 +/- 32 ml to 148 +/- 57 ml, whereas regurgitant volume remained unchanged (67 +/- 40 ml vs 65 +/- 51 ml). At baseline, the responder group had a significant higher total vascular resistance than the nonresponder group (998 +/- 538 dyne.sec.cm-5 vs 625 +/- 214 dyne.sec.cm-5; p < 0.05). With enalapril treatment, total vascular resistance in the responder group tended to decrease (891 +/- 576 dyne.sec.cm-5), but slightly increased in the nonresponder group (679 +/- 276 dyne.sec.cm-5). The control group showed no changes in regurgitant fraction, regurgitant volume, forward stroke volume, and total vascular resistance at follow-up.

Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aorta; Aortic Valve Insufficiency; Blood Flow Velocity; Case-Control Studies; Enalapril; Feasibility Studies; Follow-Up Studies; Hemodynamics; Humans; Magnetic Resonance Imaging, Cine; Reproducibility of Results